Company Overview and News

 
Bligh Resources confirms wide, high-grade gold extensions at Bundarra

2018-02-06 proactiveinvestors.com.au
Bligh Resources Ltd (ASX:BGH) has intersected significant grades and widths of gold at its Bundarra Gold Project in the Eastern Goldfields region of Western Australia.
Upvote Downvote

 
Zeta makes partial takeover bid for New Zealand Oil & Gas

2017-08-11 ogj
Singapore-based Zeta Energy Pte. Ltd., a wholly owned subsidiary of investment group Zeta Resources Ltd., has launched a partial offer for Wellington-based New Zealand Oil & Gas Ltd. (NZOG). If successful, Zeta would gain a 50.1% controlling interest in NZOG.
Upvote Downvote

 
Bligh Resources enters an ASX trading halt

2017-05-01 proactiveinvestors.com.au
Bligh Resources (ASX:BGH) was granted a trading halt by the ASX late yesterday, with its shares placed in pre-open.
Upvote Downvote

 
Bligh backs improved Zeta offer

2017-04-26 businessnews.com.au
Bligh Resources is now recommending shareholders vote in favour of Zeta Resources’ improved takeover offer, after previously backing an acquisition proposal by Saracen Mineral Holdings for its Bundarra gold project.
Upvote Downvote

 
Saracen ups bid for Bligh's gold project

2017-04-24 businessnews.com.au
Saracen Mineral Holdings has increased its offer for Bligh Resources’ Bundarra gold project after Zeta Resources made a competing bid last week.
Upvote Downvote

 
Zeta makes $8m play for Bligh

2017-04-19 businessnews.com.au
Investment group Zeta Resources has announced plans to make an all-cash takeover offer for gold-focused Bligh Resources, competing with Saracen Mineral Holdings which had agreed to buy the target’s core asset in February.
Upvote Downvote

 
Saracen to buy Bundarra project

2017-02-14 businessnews.com.au
Saracen Mineral Holdings has entered into an agreement to purchase the Bundarra gold project from Bligh Resources in an all-scrip deal worth $8.5 million.
Upvote Downvote

 
Bligh Resources in an ASX trading halt

2017-02-09 proactiveinvestors.com.au
Bligh Resources (ASX:BGH) has been granted a trading halt by the ASX this morning, pending details in relation to the disposal of the Bundarra Project.
Upvote Downvote

 
Bligh Resources to reveal drilling results from Bundarra Gold Project

2016-12-12 proactiveinvestors.com.au
Bligh has today been granted a trading halt by the ASX, pending details of drilling results.
Upvote Downvote

 
Bligh Resources to reveal material transaction

2016-12-06 proactiveinvestors.com.au
The halt will remain in place until the opening of trade on Thursday 8th December 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
Bligh Resources Ltd gets ready to raise

2016-07-14 proactiveinvestors.com.au
Bligh Resources Ltd (ASX:BGH) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare. The halt will remain in place until the opening of trade on Monday 18th July 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
 
 
Half Yearly Accounts

2016-03-15 asx.com.au
Upvote Downvote

 

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...